As a first-in-class obesity drug, Lorcaserin has the potential to have a hockey stick growth curve and become one of the best selling drugs in the last several decades. With FDA approval in hand, Arena is going to become a prime acquisition target. There is a stand still contract in place with Eisai to prevent them from acquiring Arena but don't discount the two working on a deal that is acceptable to the Arena board. Furthermore, I wouldn't be surprised if a blockbuster-hungry Big Pharma makes a move to acquire Arena and the rest of the world rights to Lorcaserin that goes with it. Sometime in Q3 or Q4, Arena could sign a partnership for Europe where it is looking for marketing authorization before the end of the year.